Aliases
CJC/Ipamorelin Stack; Mod GRF 1-29 + Ipamorelin Stack; GH Pulse Stack
Updated March 6, 2026
CJC-1295 No DAC + Ipamorelin GH Pulse Stack Protocol
Definitive combined protocol reference for GH pulse rationale, combined dosing schedules, separate-vial and blend reconstitution math, safety profile, and evidence context.
Category
Dual-Pathway GH Secretagogue Stack
Common Ratio
1:1 CJC No DAC:Ipamorelin
Cycle Length
8-12 weeks on, then 4 weeks off
Regulatory
Research compounds, not FDA-approved
CJC-1295 No DAC + Ipamorelin GH Pulse Stack Quick Reference
Category
Dual-Pathway GH Secretagogue Stack
CJC-1295 No DAC Role
GHRH receptor agonist; primes physiologic GH pulsatility (~30 minute half-life).
Ipamorelin Role
Selective GHS-R1a agonist; amplifies GH pulse without cortisol/prolactin rise (~2 hour half-life).
Typical Dose
100-200 mcg each peptide per injection
Typical Frequency
1-2x daily
Common Stack Format
1:1 dosing ratio, commonly injected together at bedtime
Route
Subcutaneous
Key Mechanistic Stat
Combines GHRH receptor signaling (CJC No DAC) with ghrelin receptor signaling (Ipamorelin) to produce stronger GH pulse output than either pathway alone.
Peptide Partners Spotlight
Featured Research Supplier
Supplier spotlight placement and ordering are controlled by the shared stack template; exact four-card affiliate block from the guide is implemented in the dedicated supplier section below.
59 Finnrick TestsMulti-Lab Verification4 Testing Categories
Affiliate disclosure: outbound supplier links may earn a commission at no extra cost to you.
Preferred Partner: Peptide Partners
What Is the CJC-1295 No DAC + Ipamorelin GH Pulse Stack?
The CJC-1295 No DAC + Ipamorelin stack is the most common two-compound GH secretagogue combination used in peptide research protocols. It pairs a short-acting GHRH analog (CJC-1295 No DAC / Mod GRF 1-29) with a highly selective GHRP (Ipamorelin) to stimulate endogenous growth hormone release through two separate receptor systems in the same dosing window.
The stack is typically used in research settings targeting sleep-related GH pulse support, body composition, and recovery-oriented protocols. Unlike CJC-1295 with DAC, the No DAC form is used here specifically to preserve pulsatile signaling rather than sustained multi-day GH elevation. That is why this combination is generally referred to as a GH pulse stack rather than a long-acting GH baseline stack.
Mechanistically, CJC-1295 No DAC stimulates pituitary GHRH receptors while Ipamorelin stimulates GHS-R1a receptors. This creates pathway complementarity: CJC provides GHRH-axis drive, and Ipamorelin adds a selective ghrelin-axis GH push without the cortisol/prolactin signal commonly associated with older GHRPs.
No randomized clinical trial has evaluated this exact two-compound stack as a combination protocol. Current use is based on individual compound data, mechanism-level synergy, and long-running community protocol conventions.
How the GH Pulse Stack Works: Dual-Receptor GH Pulse Amplification
Pathway 1: GHRH-R + GHS-R1a Dual Activation
CJC-1295 No DAC and Ipamorelin do not compete for the same receptor. CJC activates GHRH receptors on pituitary somatotrophs, while Ipamorelin activates GHS-R1a receptors in the hypothalamic-pituitary axis. Running both compounds in the same injection window increases total GH secretory drive relative to either single-pathway approach.
Pathway 2: Somatostatin Counterbalance + Pulse Height
GHRH analog signaling can reduce somatostatin tone, while Ipamorelin provides an additional GH release trigger via ghrelin pathways. Together, this creates a wider opening for GH pulses, especially during low-insulin, fasted timing windows.
Pathway 3: Short-Acting Kinetics That Favor Pulsatility
This stack intentionally uses CJC No DAC (not DAC) because rapid clearance supports discrete pulses and easier titration. If side effects occur, dose changes are felt quickly rather than lingering for days as with long-acting DAC-based protocols.
Pathway 4: Hormonal Selectivity Advantage
Ipamorelin has a cleaner endocrine profile than older GHRPs (notably less cortisol/prolactin spillover), which makes it the preferred ghrelin-pathway partner for CJC No DAC in protocols aiming for GH pulse support with less hormonal noise.
Evidence limitation: this synergy model is biologically plausible and widely used, but direct stack-level outcome trials are lacking.
CJC-1295 No DAC + Ipamorelin Dosing Protocol & Schedule
Evidence Level Notice
No clinical trial has validated this exact stack protocol for body composition, recovery, anti-aging, or performance outcomes. Dosing below reflects community-derived protocols and clinician-informed peptide practice patterns.
Standard GH Pulse Stack Schedule
Phase: Initiation
Weeks: 1-2
CJC-1295 No DAC Dose: 100 mcg
Ipamorelin Dose: 100 mcg
Frequency: 1x daily (bedtime)
Notes: Fasted dosing; establish tolerance first.
Phase: Early Titration
Weeks: 3-4
CJC-1295 No DAC Dose: 100 mcg
Ipamorelin Dose: 150-200 mcg
Frequency: 1x daily (bedtime)
Notes: Most protocols titrate Ipamorelin before increasing CJC dose.
Phase: Standard Protocol
Weeks: 5-8
CJC-1295 No DAC Dose: 100-150 mcg
Ipamorelin Dose: 150-200 mcg
Frequency: 1x daily (bedtime)
Notes: Most common maintenance range for a GH pulse stack.
Phase: Split Protocol
Weeks: 9-12 (opt)
CJC-1295 No DAC Dose: 100 mcg 2x/day
Ipamorelin Dose: 100-150 mcg 2x/day
Frequency: AM fasted + bedtime
Notes: Used when researchers want a second daytime pulse.
Phase: Off-Cycle
Weeks: 4 weeks
CJC-1295 No DAC Dose: 0 mcg
Ipamorelin Dose: 0 mcg
Frequency: -
Notes: Typical washout period after 8-12 week runs.
Weekly Timing Example (Bedtime-Only Protocol)
Day: Monday
CJC-1295 No DAC: 100-150 mcg
Ipamorelin: 150-200 mcg
Timing: 30-60 min before sleep, fasted window
Day: Tuesday
CJC-1295 No DAC: 100-150 mcg
Ipamorelin: 150-200 mcg
Timing: 30-60 min before sleep, fasted window
Day: Wednesday
CJC-1295 No DAC: 100-150 mcg
Ipamorelin: 150-200 mcg
Timing: 30-60 min before sleep, fasted window
Day: Thursday
CJC-1295 No DAC: 100-150 mcg
Ipamorelin: 150-200 mcg
Timing: 30-60 min before sleep, fasted window
Day: Friday
CJC-1295 No DAC: 100-150 mcg
Ipamorelin: 150-200 mcg
Timing: 30-60 min before sleep, fasted window
Day: Saturday
CJC-1295 No DAC: 100-150 mcg
Ipamorelin: 150-200 mcg
Timing: 30-60 min before sleep, fasted window
Day: Sunday
CJC-1295 No DAC: 100-150 mcg
Ipamorelin: 150-200 mcg
Timing: 30-60 min before sleep, fasted window
Dosing Notes
- Most protocols keep both compounds in a 1:1 or near-1:1 microgram range, with Ipamorelin sometimes slightly higher.
- Fasted administration is standard: at least 1-2 hours after the last meal, and delay food for about 20-30 minutes post-injection.
- Bedtime timing is prioritized to align with natural nocturnal GH pulses.
- If a dose is missed, resume the next scheduled dose; do not double up.
CJC-1295 No DAC + Ipamorelin Reconstitution Guide
Reconstitution Format Options
Option A: Separate Vials (Most Flexible)
Common setup: `5 mg CJC-1295 No DAC + 2.5 mL BAC water = 2,000 mcg/mL` and `5 mg Ipamorelin + 2.5 mL BAC water = 2,000 mcg/mL`.
Separate-Vial Dose Conversion
Target Stack Dose: 100 mcg + 100 mcg
CJC Volume: 0.05 mL
CJC Units (U-100): 5 units
Ipamorelin Volume: 0.05 mL
Ipamorelin Units (U-100): 5 units
Target Stack Dose: 150 mcg + 150 mcg
CJC Volume: 0.075 mL
CJC Units (U-100): 7.5 units
Ipamorelin Volume: 0.075 mL
Ipamorelin Units (U-100): 7.5 units
Target Stack Dose: 200 mcg + 200 mcg
CJC Volume: 0.10 mL
CJC Units (U-100): 10 units
Ipamorelin Volume: 0.10 mL
Ipamorelin Units (U-100): 10 units
Target Stack Dose: 100 mcg + 200 mcg
CJC Volume: 0.05 mL
CJC Units (U-100): 5 units
Ipamorelin Volume: 0.10 mL
Ipamorelin Units (U-100): 10 units
Option B: 10 mg 1:1 Blend Vial (Convenience)
Assume blend contains `5 mg CJC-1295 No DAC + 5 mg Ipamorelin`. If reconstituted with `2.0 mL BAC water`, total concentration is `5,000 mcg/mL` with `2,500 mcg/mL` per compound.
Blend Dose Conversion (Fixed 1:1)
Blend Dose Target: 100 mcg CJC + 100 mcg Ipamorelin
Total Peptide Delivered: 200 mcg total
Volume: 0.04 mL
Syringe Units (U-100): 4 units
Blend Dose Target: 150 mcg CJC + 150 mcg Ipamorelin
Total Peptide Delivered: 300 mcg total
Volume: 0.06 mL
Syringe Units (U-100): 6 units
Blend Dose Target: 200 mcg CJC + 200 mcg Ipamorelin
Total Peptide Delivered: 400 mcg total
Volume: 0.08 mL
Syringe Units (U-100): 8 units
Important: blend vials lock dosing ratio. If you want non-1:1 dosing (for example 100 mcg CJC + 200 mcg Ipamorelin), use separate vials.
Market Blend Snapshot (Web Research - March 6, 2026)
- The most common listed premix is `5 mg CJC-1295 No DAC + 5 mg Ipamorelin` (10 mg total, 1:1 ratio).
- Multiple suppliers explicitly label this as a fixed-ratio convenience blend.
- Non-1:1 blends also exist in the market (for example `12 mg/6 mg`), reinforcing the need to verify each vial's component ratio before dose math.
This is market-availability data, not clinical efficacy evidence.
Step-by-Step Reconstitution
- Gather peptide vial(s), BAC water, alcohol swabs, and U-100 insulin syringes.
- Swab vial tops and let dry.
- Draw BAC water volume.
- Inject BAC water slowly down vial wall (do not blast powder directly).
- Gently swirl/roll until clear; do not shake aggressively.
- Label vial with reconstitution date and concentration.
- Refrigerate immediately at 2-8 C.
Calculator CTA
Need exact syringe units for a different vial size or dilution? Use the Peptide Reconstitution Calculator.
CJC-1295 No DAC + Ipamorelin Side Effects - Combined Safety Considerations
Most common side effects reported in practice patterns
- Injection site redness, itching, or mild swelling
- Transient flushing or warmth
- Mild headache
- Water retention or bloating
- Sleep architecture changes (sometimes improved deep sleep, sometimes vivid dreams)
Dose-dependent behavior
Side effects generally increase with higher per-injection doses and higher daily frequency. Running conservative bedtime-only dosing first reduces early intolerance.
Additive stack considerations
- Both compounds push GH/IGF-1 pathways, so edema and insulin-sensitivity concerns can be more noticeable than with either peptide alone.
- Appetite effects are typically mild with Ipamorelin versus older GHRPs, but individual response varies.
- Because this stack is short-acting, adverse effects usually resolve faster than long-acting DAC-based protocols once dosing is reduced or paused.
Contraindication and caution profile (mechanism-based)
- Active malignancy or high cancer-risk context
- Uncontrolled diabetes or significant insulin resistance
- Significant cardiovascular disease
- Pregnancy or breastfeeding
- Known hypersensitivity to peptide excipients
Quality-control risk remains a primary safety issue: concentration errors, contamination, or degraded product quality from non-verified suppliers can create more risk than the peptide mechanism itself.
Research Evidence for the CJC-1295 No DAC + Ipamorelin Stack
There are currently no randomized controlled trials testing CJC-1295 No DAC + Ipamorelin as a combined stack protocol for performance, anti-aging, body composition, or recovery endpoints.
As of March 6, 2026, ClinicalTrials.gov records are available for CJC-family compounds and for Ipamorelin individually, but no registered interventional record was identified for this exact two-compound stack as a named intervention arm.
Evidence Hierarchy for This Stack
Evidence Layer: Direct combination trial
What Exists: None identified for this exact stack
Strength: Low
Evidence Layer: Human data - CJC family
What Exists: CJC-1295 clinical data (primarily DAC version) shows GH/IGF-1 elevation
Strength: Moderate
Evidence Layer: Human data - Ipamorelin
What Exists: PK/PD and Phase II ileus data support GH activity and short-term tolerability
Strength: Moderate
Evidence Layer: Human analog-combination evidence
What Exists: Older human studies show additive/synergistic GH release from GHRH + GHRP combinations (using GHRP-6, not Ipamorelin)
Strength: Moderate
Evidence Layer: Mechanistic synergy rationale
What Exists: Dual receptor pathway logic (GHRH-R + GHS-R1a), with extrapolation to Ipamorelin stacks
Strength: Moderate
Evidence Layer: Emerging stack-specific preclinical context
What Exists: 2026 review literature cites improved murine contractile outcomes for CJC-1295 + Ipamorelin combinations, but not human efficacy
Strength: Low-Moderate
Evidence Layer: Community protocol evidence
What Exists: Extensive anecdotal use with recurring dose conventions
Strength: Low
Practical Interpretation
- Stack popularity is driven more by mechanistic complementarity and market use than direct outcomes trials.
- Human evidence for each ingredient exists, and older GHRH+GHRP studies support pathway-level synergy, but direct CJC No DAC + Ipamorelin outcomes remain inferential.
- Early stack-specific signals are preclinical; clinical-grade claims should be avoided until direct human combination trials are available.
Storage & Handling - CJC-1295 No DAC and Ipamorelin
State: Lyophilized (unmixed)
Recommended Storage: 2-8 C (short term) or -20 C (long term)
Practical Window: Months to 1+ year (supplier dependent)
Notes: Keep dry, sealed, and light-protected.
State: Reconstituted solution
Recommended Storage: 2-8 C
Practical Window: Usually 2-4 weeks
Notes: Do not store at room temp for extended periods.
State: Prepared syringe (drawn)
Recommended Storage: Use promptly
Practical Window: Same day preferred
Notes: Avoid repeated temperature cycling.
Handling standards
- Always use bacteriostatic water for multi-dose vials.
- Use sterile single-use syringes and alcohol prep.
- Do not shake reconstituted vials.
- Discard if solution is cloudy, discolored, or contains persistent particulates.
- Use sharps disposal for all used needles and syringes.
CJC-1295 No DAC + Ipamorelin vs Single-Agent and DAC-Based Options
Feature: Pathways engaged
CJC No DAC + Ipamorelin Stack: GHRH-R + GHS-R1a
CJC-1295 No DAC Alone: GHRH-R only
Ipamorelin Alone: GHS-R1a only
CJC-1295 with DAC + Ipamorelin: Sustained GHRH + GHS-R1a
Feature: Half-life profile
CJC No DAC + Ipamorelin Stack: Short + short (pulse-focused)
CJC-1295 No DAC Alone: Short (pulse-focused)
Ipamorelin Alone: Short (pulse-focused)
CJC-1295 with DAC + Ipamorelin: Long + short (baseline + pulse)
Feature: Typical frequency
CJC No DAC + Ipamorelin Stack: 1-2x daily
CJC-1295 No DAC Alone: 1-2x daily
Ipamorelin Alone: 1-2x daily
CJC-1295 with DAC + Ipamorelin: Weekly DAC + daily Ipamorelin
Feature: Dose flexibility
CJC No DAC + Ipamorelin Stack: High with separate vials
CJC-1295 No DAC Alone: High
Ipamorelin Alone: High
CJC-1295 with DAC + Ipamorelin: Moderate (DAC component is long-acting)
Feature: Side effect persistence
CJC No DAC + Ipamorelin Stack: Usually short-lived
CJC-1295 No DAC Alone: Usually short-lived
Ipamorelin Alone: Usually short-lived
CJC-1295 with DAC + Ipamorelin: DAC-related effects can persist days
Feature: Best use-case fit
CJC No DAC + Ipamorelin Stack: Balanced GH pulse amplification
CJC-1295 No DAC Alone: GHRH-only pulse support
Ipamorelin Alone: Selective ghrelin-pathway support
CJC-1295 with DAC + Ipamorelin: Convenience plus sustained exposure
Comparison summary: for protocols that specifically want physiologic pulse-style signaling and rapid dose adjustability, CJC No DAC + Ipamorelin remains the preferred stack architecture over DAC-based combinations.
COA-Verified Suppliers Carrying CJC-1295 No DAC and Ipamorelin
- Orbitrex Peptides - COA-verified supplier carrying CJC-1295 No DAC and Ipamorelin in separate and stack formats. Visit Site -> | Code: PEPPAL
- Paradigm Peptides - Published batch COAs with U.S.-based fulfillment and common GH stack inventory. Visit Site -> | Code: PEPPAL
- Pivot Labs - Research-grade peptide catalog with lot-level testing documentation. Visit Site -> | Code: PEPPAL
- Peptide Tech - Supplier with third-party purity reporting and frequent stack bundle availability. Visit Site -> | Code: PEPPAL
Affiliate Disclosure
Some supplier links are affiliate links. We may earn a commission at no extra cost to you. This supports free tools and protocol resources. Editorial standards remain independent of affiliate relationships.
Frequently Asked Questions - CJC-1295 No DAC + Ipamorelin GH Pulse Stack
Q1: What is the CJC-1295 No DAC + Ipamorelin GH Pulse Stack?
It is a two-peptide GH secretagogue stack that combines CJC-1295 No DAC (GHRH analog) and Ipamorelin (selective GHS-R1a agonist). The goal is to trigger stronger physiologic GH pulses through complementary receptor pathways rather than sustained, long-acting GH elevation.
Q2: Why is CJC-1295 No DAC used instead of CJC-1295 with DAC in this stack?
No DAC is short-acting and pulse-oriented. That allows tighter timing around sleep and meals, easier titration, and faster reversal of side effects if dosing is adjusted. DAC versions are longer-acting and better suited to sustained baseline protocols rather than discrete pulse-focused stacking.
Q3: What is a common starting dose for the GH Pulse Stack?
A common initiation protocol is 100 mcg CJC No DAC + 100 mcg Ipamorelin once nightly for 1-2 weeks. Many protocols then titrate to 100-150 mcg CJC and 150-200 mcg Ipamorelin.
Q4: Should CJC-1295 No DAC and Ipamorelin be injected at the same time?
Most protocols administer both in the same dosing window, typically 30-60 minutes before sleep while fasted. This aligns both pathway signals for a stronger single GH pulse.
Q5: Can both peptides be drawn into the same syringe?
Many users do this after separate vial reconstitution for convenience, but separate syringes provide maximum dosing control and reduce compatibility concerns. If using fixed-ratio blend vials, ratio flexibility is limited by design.
Q6: What injection timing is most common for this stack?
Bedtime fasted dosing is the most common. Some advanced protocols add a second morning fasted dose, but most users keep the protocol bedtime-only initially.
Q7: How long should a CJC-1295 No DAC + Ipamorelin cycle run?
Typical cycle length is 8-12 weeks followed by around 4 weeks off. Longer runs are sometimes used, but most protocols cycle to maintain responsiveness and reassess tolerance.
Q8: What results timeline is typically reported with this stack?
Anecdotal reports commonly describe sleep/recovery changes within 1-3 weeks, with body-composition changes more often discussed after 6-12 weeks. These outcomes are not validated by direct stack trials.
Q9: Is this stack clinically proven?
Not as a direct two-compound protocol. Human data exists for each ingredient, but combination efficacy claims are extrapolated from mechanism and single-agent evidence, not stack-level randomized outcomes.
Q10: What side effects are most common in the GH Pulse Stack?
Most common reported effects are injection-site irritation, flushing, headache, and mild water retention. Side effects are usually dose-dependent and often improve with lower dosing or reduced frequency.
Q11: How do you reconstitute a 10 mg 1:1 CJC-1295 No DAC + Ipamorelin blend?
If the vial contains 5 mg of each peptide (10 mg total), adding 2.0 mL BAC water yields 2,500 mcg/mL of each peptide. At that concentration, 4 units gives 100 mcg + 100 mcg, 6 units gives 150 mcg + 150 mcg, and 8 units gives 200 mcg + 200 mcg.
Q12: Who should avoid this stack?
Anyone with active malignancy, uncontrolled diabetes, significant cardiovascular disease, pregnancy/breastfeeding status, or known peptide hypersensitivity should avoid unsupervised use. This protocol is for research reference only and is not medical advice.
Sources & Research
- Teichman SL, Neale A, Lawrence B, et al. "Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults." Journal of Clinical Endocrinology & Metabolism, 2006 Link.
- Ionescu M, Frohman LA. "Pulsatile Secretion of Growth Hormone Persists during Continuous Stimulation by CJC-1295." Journal of Clinical Endocrinology & Metabolism, 2006 Link.
- Jette L, Leger R, Thibaudeau K, et al. "Identification of CJC-1295 as a Long-Lasting GRF Analog." Endocrinology, 2005 Link.
- Gobburu JV, Agerso H, Jusko WJ, Ynddal L. "Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin in Human Volunteers." Pharmaceutical Research, 1999 Link.
- Raun K, Hansen BS, Johansen NL, et al. "Ipamorelin, the First Selective Growth Hormone Secretagogue." European Journal of Endocrinology, 1998 Link.
- Beck DE, Sweeney WB, McCarter MD. "Ipamorelin for Postoperative Ileus in Bowel Resection Patients." International Journal of Colorectal Disease, 2014 Link.
- Mayfield CK, Bolia IK, Feingold CL, et al. "Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians." American Journal of Sports Medicine, 2026 Link.
- Micic D, Popovic V, Kendereski A, et al. "Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood." Clinical Endocrinology, 1995 Link.
- Villas-Boas Weffort RF, Ramos-Dias JC, Chipoch C, Lengyel AM. "Growth hormone (GH) response to GH-releasing peptide-6 in patients with insulin-dependent diabetes mellitus." Metabolism, 1997 Link.
- Ishida J, Saitoh M, Ebner N, et al. "Growth Hormone Secretagogues: History, Mechanism of Action, and Clinical Development." JCSM Rapid Communications, 2020 Link.
- ClinicalTrials.gov "Ipamorelin in Postoperative Ileus." Identifier: NCT00672074. Clinical Trial Registry, n.d. Link.
- ClinicalTrials.gov "Safety and Efficacy of Ipamorelin Compared to Placebo for Recovery of Gastrointestinal Function." Identifier: NCT01280344. Clinical Trial Registry, n.d. Link.
- ClinicalTrials.gov "A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity." Identifier: NCT00267527. Clinical Trial Registry, n.d. Link.
- FDA "Tailor Made Compounding LLC - 594743 - 04/01/2020." Warning Letter, 2020 Link.
- FDA "Innoveix Pharmaceuticals, Inc. Issues Voluntary Recall of All Sterile Compounded Drug Products Due to A Lack of Sterility Assurance." Recall Notice, n.d. Link.
- BlueWell Peptides "CJC-1295 No DAC + Ipamorelin 10mg Blend (5mg/5mg)." Market Listing, 2026 Link.
- Blue Sky Peptide "Blend CJC 1295 NO DAC 5MG with Ipamorelin 5MG." Market Listing, 2026 Link.
- Limitless Life Nootropics "CJC-1295 + Ipamorelin Blend (12mg Ipamorelin / 6mg CJC-1295 No DAC)." Market Listing, 2026 Link.
Related Protocols
~30 minutes
CJC-1295 No DAC
GHRH Analog
View protocol~2 hours
Ipamorelin
GHRP (GHS-R1a agonist)
View protocol~6-8 days
CJC-1295 with DAC
Long-acting GHRH analog
View protocol~26 minutes
Tesamorelin
GHRH analog
View protocol~10-20 minutes
Sermorelin
GHRH analog
View protocol~20-30 hours
IGF-1 LR3
IGF pathway peptide
View protocolDisclaimer
The information on this page is for educational and research reference purposes only. CJC-1295 No DAC and Ipamorelin are not FDA-approved for any indication. No compounds discussed on this site are intended for human consumption. This content is not medical advice and does not replace qualified clinical care.
This page contains affiliate links to vetted suppliers. We may earn a commission at no extra cost to you. Editorial standards and protocol structure are independent of affiliate relationships.